Ricardo Londono serves as the CEO of Organoid Therapeutics. Within Organoid Therapeutics, they envisage a future where artificial organs can be mass-produced, serving as the primary treatment option for patients with end-stage organ diseases. Their mission encompasses the development of artificial organ technologies, coupled with contributions to education for future generations and the advancement and production of technology within the United States.